Europe INfocus with Aboagye Mintah: Why the EU is betting on country to lead Africa’s vaccine revolution

…How a partnership with Europe is helping Ghana move from importing vaccines to making them

When the COVID-19 pandemic swept across the world, it exposed a painful reality for many African countries. When a global health crisis strikes, Africa is often left waiting.

While wealthier nations secured vaccines for their populations, many African countries faced long delays before doses became available. For countries like Ghana, the experience raised an important question. Why should a continent of over a billion people remain dependent on others for some of its most critical healthcare needs?

Today, Ghana is part of a growing effort to change that story.

Through a major partnership with the European Union (EU), the country is taking meaningful steps towards becoming a producer, not just a consumer, of vaccines and other health technologies. It is an ambitious journey, but one that could transform Ghana’s healthcare sector, create high-value jobs, and strengthen the country’s ability to respond to future health emergencies.

A New Vision for Ghana

Ghana wants to build the capacity to manufacture vaccines and other medical products locally. This is not only about healthcare, it is also about economic development, industrialisation, innovation, and national resilience.

At the centre of this effort is the EU-supported MAV+ initiative. Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa.

The initiative forms part of a broader European commitment to support Africa’s pharmaceutical and health manufacturing ambitions.

Why Vaccine Manufacturing Matters

Many people hear the term “vaccine manufacturing” and immediately think of laboratories and scientists in white coats.

But building a vaccine industry requires far more than that.

It involves:

• Advanced manufacturing facilities
• Highly skilled scientists and technicians
• Strong regulatory systems
• Quality assurance mechanisms
• Supply chain management
• Research and development capacity
• International partnerships

In short, it creates an entire ecosystem of knowledge, skills, and economic activity.

For Ghana, this presents an opportunity to move into a high-value industry that few countries on the continent currently possess.

It also means that future generations of Ghanaian scientists, engineers, pharmacists, biotechnologists, and healthcare professionals could build careers in a sector that barely existed locally a decade ago.

The EU’s Long-Term Commitment

One of the most significant aspects of this initiative is the scale of support being provided.

Under the EU’s Global Gateway strategy, more than €1 billion has been mobilised across Africa to strengthen vaccine, pharmaceutical, and health technology manufacturing.

Ghana has emerged as one of the countries expected to play a leading role in this vision.

Rather than focusing solely on constructing facilities, the partnership aims to build the complete foundation needed for a sustainable industry.

That includes:

• Technical training
• Skills development
• Regulatory strengthening
• Research partnerships
• Manufacturing infrastructure
• Technology transfer
• Market development

In other words, the goal is not simply to build factories. The goal is to build an industry.

More Than Funding

Perhaps the most important aspect of the EU-Ghana partnership is that it goes beyond financial support. Money alone cannot create a successful pharmaceutical sector. One critical area receiving attention is regulation.

For any vaccine produced in Ghana to be trusted locally or exported internationally, it must meet the highest quality and safety standards.

That is why significant effort is being invested in strengthening Ghana’s Food and Drugs Authority (FDA). The objective is to ensure that products manufactured in Ghana meet the same rigorous standards expected anywhere in the world. This may not attract headlines, but it is one of the most important pieces of the puzzle. Without strong regulation, there can be no globally competitive pharmaceutical industry.

Creating Jobs for the Next Generation

For young Ghanaians, the implications are particularly exciting. Every new industry creates opportunities, but few create opportunities as diverse as pharmaceutical manufacturing.

The sector requires scientists, engineers, data analysts, laboratory technicians, regulatory specialists, quality control professionals, logistics experts, project managers etc. As Ghana develops local manufacturing capacity, entirely new career paths are emerging. This is especially important at a time when many young graduates are seeking opportunities in specialised industries with strong growth potential.

Rather than leaving the country to pursue opportunities abroad, more young professionals may soon find world-class opportunities here at home.

Lessons from COVID-19

The pandemic taught the world many lessons. One of the biggest was that healthcare security is now as important as economic security. Countries that could produce vaccines quickly were better positioned to protect lives, reopen economies, and recover faster.

For Ghana, local manufacturing offers protection against future global disruptions. Instead of waiting months for vaccines or medical supplies to arrive, the country would have greater control over production and distribution. This is sometimes referred to as “health sovereignty”, the ability of a country to meet critical healthcare needs using its own capabilities.

In a world where future pandemics remain a possibility, that capability is becoming increasingly valuable.

A Regional Opportunity

The opportunity extends beyond Ghana’s borders. The African Union has set an ambitious goal of producing 60 percent of Africa’s vaccine needs locally by 2040. If successful, Ghana could become one of the continent’s key manufacturing and distribution hubs.

This would not only improve healthcare outcomes but also strengthen Ghana’s position as a regional centre for innovation, science, and advanced manufacturing. The economic impact could be substantial.

A thriving pharmaceutical sector has the potential to attract investment, generate exports, create skilled jobs, and support broader industrial development.

Looking Ahead

The road ahead will not be simple. Building a globally competitive vaccine industry takes time, patience, expertise, and sustained investment. But for perhaps the first time, Ghana has both a clear vision and strong international partners helping to make that vision a reality.

The EU’s support is not merely helping Ghana build factories. It is helping to build skills, institutions, systems, and opportunities that could benefit the country for decades to come.

The real story here is bigger than vaccines. It is about Ghana positioning itself for the future. It is about creating industries that generate knowledge, innovation, and high-quality jobs. And it is about ensuring that the next time the world faces a major health crisis, Ghana is not waiting at the end of the line, but standing among the countries helping to provide the solution.

Post Views: 43